Loading…
Ecovyst Inc.
NYSE: ECVT Materials Chemicals 🔎 Screen
$1.2B
Market Cap
16.3
P/E
1.12
PEG
1.4%
ROCE
1.0%
ROE
0.70
D/E
9.0%
OPM
-32.7%
% from 52W High
32
α RS
🔍 ECVT is showing a sector-leadership setup because Sector RRG has Materials in the Leading quadrant with the trail still strengthening, it matches 2 of 37 tracked screener presets, and an ECS of 72 last quarter. Net: Broad signal stack, not a recommendation. ? RRG Conviction ECS
Sources
Materials in Leading quadrant · Conviction 2/37 · ECS 72
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for ECVT including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Ecovyst Inc. offers virgin and regenerated sulfuric acid products and services in the United States and internationally.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding ECVT
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 1.05M $13.5M 0.02% Mar 2026
Jim Simons Renaissance Technologies LLC 306.7K $3.9M 0.01% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
📊 MIXED Ecovyst Q1 2026: EBITDA up 87% to $40M; Calabrian acquisition for $190M.
Revenue & Profitability
Q1 2026 sales were $215 million, up 50% YoY, partly due to a $33 million sulfur cost pass-through. Adjusted EBITDA was $40 million, up 87%. Adjusted free cash flow was $4 million. Net debt leverage stood at 1.2x. For full year 2026, management guided sales of $890-$970 million, adjusted EBITDA of $180-$195 million, and adjusted free cash flow of $40-$55 million.
Outlook
Management expects favorable demand trends for 2026 with high U.S. refinery utilization and less customer downtime, supporting regeneration services. Virgin sulfuric acid benefits from multiyear mining expansions and onshoring. Sulfur costs reached all-time highs due to the Iran conflict, but the company passes through sulfur costs to customers, minimizing EBITDA impact. The geopolitical environment remains dynamic but is seen as a tailwind for utilization.
Growth Drivers
Growth is driven by regeneration services volume from high refinery alkylation economics and lower planned downtime. Virgin sulfuric acid sales grow from increased mining demand and the full-year contribution of the Waggaman site (acquired May 2025). The Calabrian acquisition adds sulfur dioxide and derivatives for mining, water treatment, pharma, and food processing. Revenue synergies are expected from combined sales forces and cross-selling.
Balance Sheet & CapEx
Ecovyst is investing in expansion of Gulf Coast storage and logistics capabilities to serve customer growth (no specific amount provided). The $190 million acquisition of Calabrian will be funded with cash on hand and a debt offering, with an expected pro forma net debt leverage of ~2x. No other capital expenditure guidance was discussed.
Margins
Adjusted EBITDA margin improved in Q1 due to higher volume and favorable pricing, with a net price-to-cost uplift of approximately $11 million excluding the sulfur pass-through. The sulfur cost pass-through is neutral to EBITDA but lowers margin percentage. Management expects the positive price-to-cost ratio to continue throughout 2026.
Key Risks
Risks include a dynamic geopolitical and macroeconomic environment (e.g., Iran conflict) leading to sulfur cost spikes. While sulfur is passed through, timing differences can create temporary benefits or headwinds. Lower virgin sulfuric acid volume is expected in H2 2026 due to timing of nylon sales and lower pass-through pricing in Q4. Higher turnaround costs are anticipated in the second half.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-08-05
Q2 2026 saw strong sales and EBITDA growth, driven by robust sulfuric acid demand and favorable pricing. The Calabrian acquisition closed, expanding the portfolio and expected to be accretive, with integration on track. Full-year guidance was raised for sales, EBITDA, and free cash flow.
Q1 2026 Q1 2026 2026-05-05
Strong Q1 growth in regeneration services and virgin sulfuric acid drove a 50% sales increase and 87% higher adjusted EBITDA year-over-year. Guidance for 2026 was raised, and the Calabrian acquisition is set to expand the product portfolio and market reach.
Q4 2025 Q4 2025 2026-02-26
Strong Q4 and full-year 2025 results exceeded guidance, driven by higher sulfuric acid sales and favorable pricing. The business was transformed by a major divestiture, debt reduction, and strategic acquisitions, positioning for growth in 2026 with a robust balance sheet and active capital returns.
Q3 2025 Q3 2025 2025-11-04
Announced sale of a major segment to Technip Energies, with proceeds to reduce debt and fund growth. Q3 saw strong sales and EBITDA growth, driven by pricing and mining demand, despite refinery outages. 2025 guidance raised for free cash flow, with a focus on organic growth, capital returns, and a strengthened balance sheet.
Q2 2025 Q2 2025 2025-08-07
Q2 2025 saw strong financial results, with sales and EBITDA exceeding guidance, driven by stable demand, the Waggaman acquisition, and robust performance in hydrocracking catalysts. Guidance for full-year sales, Zeolyst JV, and free cash flow was raised, while leverage increased due to acquisitions and share repurchases.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.